SINGAPORE-BASED startup AWAK Technologies has raised more than US$20 million in Series B funding, the company said on Wednesday (Sep 13).

Venture capital (VC) firms Lion X Ventures and Vickers Venture Partners co-led the round, which also received participation from other investors such as Temasek-backed Advanced MedTech and US-based healthcare VC fund Eckuity Capital.

The funds will be used to conclude the startup’s ongoing human pre-pivotal clinical trial with Singapore General Hospital and improve its ultraportable peritoneal dialysis (PD) device in preparation for a final pivotal trial in the US.

The funds will also be used to develop new products such as complementary items for home dialysis, and implement digital solutions to enhance home-based care for chronic kidney disease patients.

AWAK focuses on dialysis using regeneration technology for end-stage renal disease. It said its patented technologies can cut the amount of dialysis fluid required by up to 90 per cent.

AWAK has also miniaturised the typical large-sized dialysis machine to fit into a small carry bag, producing a wearable PD device that allows patients to go through dialysis at home and on the move.

GET BT IN YOUR INBOX DAILY

Start and end each day with the latest news stories and analyses delivered straight to your inbox.

Sign UpVIEW ALL

“The next-generation dialysis solution ought to not only be lifesaving but also restore productivity and dignity with convenience and ease for the millions of end-stage renal disease patients,” said Irene Guo, co-chief executive of Lion X Ventures.